Old and new serological tests for celiac disease screening

Area of Science:

• Gastroenterology
• Immunology
• Clinical Diagnostics

Background:

• Celiac disease (CD) involves an immune response to deamidated gliadin peptides (DGP) generated by tissue transglutaminase (tTG).
• Serological tests detecting antibodies to DGP and tTG are used for CD screening.
• A meta-analysis compared the diagnostic performance of DGP and tTG antibodies for CD.

Discussion:

• This meta-analysis evaluated IgA class antibodies for CD screening.
• Methodological limitations, including ascertainment bias, were noted in the included studies.
• The study compared the sensitivity and specificity of DGP versus tTG antibody tests.

Key Insights:

• Pooled sensitivity for DGP antibodies was 87.8% (95% CI: 85.6-89.9) and for tTG antibodies was 93% (95% CI: 91.2-94.5).
• Pooled specificity for DGP antibodies was 94.1% (95% CI: 92.5-95.5) and for tTG antibodies was 96.5% (95% CI: 95.2-97.5).
• tTG antibodies demonstrated a higher predictive value than DGP antibodies for celiac disease.

Outlook:

• tTG antibody testing remains the gold standard for celiac disease serological screening.
• Further research may explore optimizing DGP antibody assays or their use in conjunction with tTG testing.
• Improved study designs are needed to minimize bias in future meta-analyses of CD serological markers.